» Articles » PMID: 22511903

Analysis of Prognostic Factors and 5-year Survival Rate in Patients with Hepatocellular Carcinoma: a Single-center Experience

Abstract

Background/aims: Hepatocellular carcinoma (HCC), which is the third most common cancer in Korea, has a very poor prognosis. However, only a few studies have performed a comprehensive survival-related analysis in all patients who were consecutively diagnosed and treated over a given period of time. The aim of this study was to determine the 5-year survival rate and its prognostic factors among HCC patients.

Methods: In total, 257 patients who were consecutively diagnosed with HCC between January 2000 and December 2003 were followed until death or until December 2008. We analyzed their survival outcomes according to their clinical characteristics, tumor staging, and treatment modalities, and determined the independent prognostic factors affecting survival.

Results: The patients were aged 59±10 years (mean±SD). During the follow-up period, 223 patients (86.8%) died and the overall median survival was 10.8 months; the 1-, 3-, and 5-year survival rates were 44.4%, 21.0%, and 12.1%, respectively. The outcomes in patients with tumor node metastasis (TNM) stage I or II and Child-Pugh class A or B were significantly better with surgical resection than with other treatment modalities (P<0.01). Patients who underwent supplementary transcatheter arterial chemoembolization as a second-line treatment after surgical resection had better outcomes than those who underwent surgical resection alone (P=0.02). Initial symptoms, Child-Pugh class, serum alpha-fetoprotein, tumor size, portal vein thrombosis, and TNM stage were found to be independent prognostic factors for survival among HCC patients.

Conclusions: This retrospective cohort study elucidated survival outcomes and prognostic factors affecting survival in HCC patients at a single center.

Citing Articles

Integrated Analysis Revealing the Senescence-Mediated Immune Heterogeneity of HCC and Construction of a Prognostic Model Based on Senescence-Related Non-Coding RNA Network.

Jiang Y, Luo K, Xu J, Shen X, Gao Y, Fu W Front Oncol. 2022; 12:912537.

PMID: 35847928 PMC: 9279728. DOI: 10.3389/fonc.2022.912537.


Comprehensive Analysis of Prognostic Value and Immune Infiltration of the NT5DC Family in Hepatocellular Carcinoma.

Li R, Liu R, Zheng S, Liu W, Li H, Li D J Oncol. 2022; 2022:2607878.

PMID: 35047040 PMC: 8763557. DOI: 10.1155/2022/2607878.


Hepatocellular Carcinoma (HCC) in North-Western India: A Retrospective Study Focusing on Epidemiology, Risk Factors, and Survival.

Soni S, Pareek P, Narayan S, Rakesh A, Abhilasha A J Gastrointest Cancer. 2021; 53(4):921-929.

PMID: 34550547 DOI: 10.1007/s12029-021-00712-z.


Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma - A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients.

Jensen C, Holm Nielsen S, Eslam M, Genovese F, Nielsen M, Vongsuvanh R J Hepatocell Carcinoma. 2020; 7:301-313.

PMID: 33204663 PMC: 7665576. DOI: 10.2147/JHC.S275008.


Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma.

Elshaarawy O, Alkhatib A, Elhelbawy M, Gomaa A, Allam N, Alsebaey A World J Hepatol. 2019; 11(6):542-552.

PMID: 31293722 PMC: 6603504. DOI: 10.4254/wjh.v11.i6.542.


References
1.
Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y . Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000: analysis of 1365 patients in a single institution in Japan. Cancer. 2004; 100(11):2415-21. DOI: 10.1002/cncr.20289. View

2.
Song I, Kim K . Current status of liver diseases in Korea: hepatocellular carcinoma. Korean J Hepatol. 2009; 15 Suppl 6:S50-9. DOI: 10.3350/kjhep.2009.15.S6.S50. View

3.
Park K, Park J, Choi J, Kim T, Kim S, Park H . Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol. 2007; 23(3):467-73. DOI: 10.1111/j.1440-1746.2007.05112.x. View

4.
Park K, Park J, Kim T, Choi J, Kim S, Park H . [Five-year survival analysis of a cohort of hepatocellular carcinoma patients who treated at the National Cancer Center, Korea]. Korean J Hepatol. 2007; 13(4):530-42. DOI: 10.3350/kjhep.2007.13.4.530. View

5.
Park Y, Kim B, Wang H, Kim M . Hepatic resection for hepatocellular carcinoma meeting Milan criteria in Child-Turcotte-Pugh class a patients with cirrhosis. Transplant Proc. 2009; 41(5):1691-7. DOI: 10.1016/j.transproceed.2008.07.146. View